Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MabCampath-1h · 1 trial · 1 indication
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.
| Arm | Type | Description |
|---|---|---|
| MabCampath-1h | EXPERIMENTAL | Single arm, single cohort study, all subjects will be dosed with alemtuzumab. |
| Name | Type | Description |
|---|---|---|
| MabCampath-1h | DRUG | Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days. |
Inclusion Criteria: * Signed, informed consent form * Age 18 to 50 years old (inclusive) * Diagnosis of MS per update of McDonald criteria, and cranial MRI scan demonstrating white matter lesions attributable to MS within 10 years of screening * Onset of MS symptoms within 15 years of screening * N...
MabCampath-1h is an investigational small molecule being developed for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). It is currently in Phase 3 clinical development, though the specific therapeutic mechanism has not been disclosed. The drug is being studied to evaluate its effects on patients with this condition.
MabCampath-1h is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker symbol SNY. Sanofi is responsible for the clinical development and regulatory strategy for this investigational drug candidate.
MabCampath-1h is currently in Phase 3 clinical development for Relapsing Remitting Multiple Sclerosis. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under evaluation.
MabCampath-1h has been studied in one completed Phase 3 clinical trial with the identifier NCT01307332. The trial, titled 'Advanced MRI Measures of Repair in Alemtuzumab Treated Patients,' enrolled 27 participants with Relapsing Remitting Multiple Sclerosis in Canada. The study was uncontrolled and not blinded.
MabCampath-1h is associated with the drug alemtuzumab, as indicated by the clinical trial title referencing 'Alemtuzumab Treated Patients.' However, the drug is being developed under the name MabCampath-1h by Sanofi for Relapsing Remitting Multiple Sclerosis. The relationship between these names suggests they refer to the same therapeutic agent.